Amanda Poliseno

Amanda Poliseno

Auto-generated profile, based on publicly available information

Amanda Poliseno

Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill North Carolina USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2025 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
ADAaron S. Devanathan
Aaron S. Devanathan
APAmanda J. Bs Poliseno
Amanda J. Bs Poliseno
NWNicole R. White
Nicole R. White
ASAmanda Panty Schauer
Amanda Panty Schauer
CSCraig Sykes
Craig Sykes
MCMackenzie L Cottrell
Mackenzie L Cottrell
Background: Incomplete adherence to daily tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) reduces effectiveness. Adherence biomeasures (ie, drug concentrations in biological specimen) are more accurate than self-report. TDF/FTC's intracellular active metabolites (tenofovir-diphosphate; TFVdp and FTC-triphosphate; FTCtp) can be quantified in different types of blood samples to estimate adherence. To optimize adherence estimation, we investigated approaches to measure TFVdp and FTCtp in 4 blood matrices. Methods: Twelve HIV-negative, healthy volunteers were enrolled in a single-center, open-label, 3-phase, directly observed therapy study. LC-MS/MS methods quantified TFVdp/FTCtp in dried blood spots, volumetrically accurate microsampling, upper layer packed cells, and peripheral blood mononuclear cells (PBMCs). Noncompartmental analysis estimated half-lives and accumulation ratios. Correlations characterized relationships between clinical variables and exposure. Regression models were fit to determine concentrations associated with <4 and ≥4 doses/week; correct classification percentages were determined. Results: Terminal half-life estimates of 3–4 vs 15–22 days distinguished between moderate-term (FTCtp in all samples; TFVdp in PBMCs) versus long-term (TFVdp in red blood cell–containing matrices) measures. Model-derived thresholds accurately categorized <4 and ≥4 doses/week when including both metabolites for 14- and 28-day dosing periods (81%–91% and 82%–85%, respectively). Within each classification and regression trees analyses containing both moderate- and long-term measures, dried blood spots exhibited highest accuracy to predict stable (74%–94%) and changing (42%–47%) adherence patterns. Conclusions: We demonstrate higher accuracy of moderate-term biomeasures to classify adherence over a 14-day period compared with long-term biomeasures to classify adherence over a 28-day period. Combined moderate- and long-term biomeasures predicted stable and changing adherence patterns, with dried blood spots exhibiting highest accuracy.

21 April 2023 in JMIR Research Protocols
Verified
Journal Article
Open access
APAmanda Poliseno
Amanda Poliseno
EFElla Ferguson
Ella Ferguson
RPRose Perry
Rose Perry
AMAlexandra Munson
Alexandra Munson
ADAlexandra Davis
Alexandra Davis
AKAngela Kashuba
Angela Kashuba
Background: Adherence to antiretroviral (ARV) therapy is critical for achieving HIV RNA suppression in people living with HIV and for preventing HIV infection in uninfected individuals using preexposure prophylaxis. However, a high level of adherence can be challenging to achieve for people living with HIV on lifelong ARVs and for HIV-negative individuals using daily preexposure prophylaxis who are not at daily risk for HIV infection. Current biological measures of adherence are invasive and use bioanalytical methods that do not allow for real-time feedback during a clinic visit. This study was designed to test the feasibility and acceptability of using MedViewer, a novel, minimally invasive, hair-based assay that measures longitudinal ARV drug adherence in real time and provides an output for provider-patient discussion. Objective: The primary objectives were to investigate the feasibility of delivering the MedViewer results as planned, the acceptability of participation in a discussion of the MedViewer results, and the appropriateness of using MedViewer for adherence counseling. The secondary objectives were to investigate additional dimensions of feasibility, acceptability, and appropriateness of using the MedViewer test during a routine clinic visit for people with HIV. Methods: The proposed study was a single-arm cross-sectional study among patients receiving HIV care and providers of HIV care in a southeastern infectious disease clinic. The study originally planned to implement the MedViewer test with 50 eligible patients who were living with HIV across 2 viral load strata (undetectable or detectable plasma HIV RNA over the previous 2 years), administer brief visit-specific questionnaires to all patient and provider participants, and conduct qualitative in-depth interviews and quantitative end-line questionnaires with a subsample of patient participants (n=30) and all provider participants. Results: The Establishing Novel Antiretroviral Imaging for Hair to Elucidate Nonadherence study was funded by the National Institute of Allergy and Infectious Diseases and approved by the local institutional review board on November 4, 2019. Provider participant enrollment began on January 17, 2020, and patient participant enrollment began on January 22, 2020. Participant enrollment was halted on March 16, 2020, because of the COVID-19 pandemic (16 providers and 10 patients on study). Study activities resumed on February 2, 2021, with COVID-19 modifications approved by the local institutional review board. Participant enrollment closed on October 8, 2021, and data collection closed on November 15, 2021. In total, 36 unique patient participants, representing 37 samples, and 20 provider participants were enrolled. Data analysis and manuscript writing will take place throughout 2023. Conclusions: We anticipate that the data collected through this study will provide important insights regarding the feasibility, acceptability, and appropriateness of incorporating new real-time longitudinal, minimally invasive adherence tests into routine clinical care and identify potential barriers to medication adherence among patients. Trial Registration: ClinicalTrials.gov NCT04232540; https://clinicaltrials.gov/ct2/show/NCT04232540 International Registered Report Identifier (IRRID): RR1-10.2196/41188

10 July 2026 in JMIR Research Protocols
Verified
Journal Article
Open access
APAmanda Poliseno
Amanda Poliseno
LRLisa Rahangdale
Lisa Rahangdale
CGCynthia Gay
Cynthia Gay
EREmma Trawick Roberts
Emma Trawick Roberts
AKAngela Kashuba
Angela Kashuba
Background: Women are largely underrepresented in clinical trials of antiretroviral therapy, constituting approximately 20% of participants. Trials often exclude pregnant women from participation to minimize fetal risk, and women enrolled in clinical trials who have a positive pregnancy test may be discontinued from the study. This results in an average 7-year lag between the time of drug approval and when dosing information for pregnancy is available. However, there may be low-risk opportunities to obtain dosing information earlier for pregnant women who need treatment with newer medications. We demonstrate this with a clinical trial of doravirine, a Food and Drug Administration (FDA)–approved nonnucleoside reverse transcriptase inhibitor, designed to assess the pharmacokinetics and dosing strategy for doravirine during pregnancy while maintaining safety for participants. Objective: The primary objective of this study is to quantify single-dose total and protein-unbound pharmacokinetics of doravirine in blood plasma from women living with HIV during their second trimester, third trimester, and postpartum periods. The secondary objective is to evaluate the safety and tolerability of single doses of doravirine in pregnant participants living with HIV. Methods: The proposed study is a single-site phase 1 evaluation of single doses of doravirine across the gestational period in pregnant female participants (n=10) living with HIV currently controlled with antiretroviral therapy. Single doses were administered in the second and third trimesters and postpartum. Pharmacokinetic sampling occurred over a 72-hour dosing interval, and total and protein-unbound drug concentrations were assessed across the 3 dosing phases using LC-MS/MS methods validated according to FDA criteria. Pharmacokinetic parameters of peak drug concentration, concentration at 12 hours into the dosing interval, concentration at the end of the dosing interval, time to reach maximum concentration, and area under the curve were estimated using noncompartmental linear up-log down methods (version 8.6; Phoenix WinNonlin). Comparisons across the 3 sampling visits were made using the Friedman test and post hoc Wilcoxon signed-rank tests with Bonferroni adjustment (version 13.0; SigmaPlot). Results: The proposed study was funded in 2020 and approved by the University of North Carolina-Chapel Hill institutional review board on March 9, 2021. Participant recruitment began the same day, and the first participant was enrolled on June 9, 2022. The last participant was enrolled on October 3, 2024, and all participants were off the study on April 8, 2025. In total, 7 participants were enrolled in the study, and 5 were evaluable. Conclusions: The data collected with this novel single-dose pharmacokinetic study design will provide important insights into the clinical management of patients on doravirine during pregnancy and provide an effective model for obtaining early pharmacokinetic and dosing information for new drugs that can be used in pregnant women.

26 September 2026 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
APAmanda Poliseno
Amanda Poliseno
LRLisa Rahangdale
Lisa Rahangdale
ASAmanda Schauer
Amanda Schauer
CSCraig Sykes
Craig Sykes
CGCynthia Gay
Cynthia Gay
AKAngela D M Kashuba
Angela D M Kashuba
Physiological changes during pregnancy may alter the pharmacokinetics of antiretrovirals, but pregnancy pharmacokinetic/dynamic data may lag years after drug approval. This single-dose approach allows for earlier data generation, estimating total and protein-unbound doravirine pharmacokinetics in women with human immunodeficiency virus during their second trimester, third trimester, and postpartum. Pregnancy may alter pharmacokinetics of antiretrovirals, but pharmacokinetic/dosing recommendations can lag years after drug approval. Our approach, measuring single-dose (and estimating steady-state) total and protein-unbound doravirine pharmacokinetics in pregnant women with human immunodeficiency virus, can safely generate early data.


27 September 2026 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
LTLauren A. R. Tompkins
Lauren A. R. Tompkins
APAmanda Poliseno
Amanda Poliseno
AWAirlie Ward
Airlie Ward
EBEdward P. Browne
Edward P. Browne
CGCassandra Gilbert
Cassandra Gilbert
MCMackenzie L Cottrell
Mackenzie L Cottrell
Romidepsin (RMD), an FDA‐approved histone deacetylase inhibitor for treating cancer, demonstrates potent latency‐reversing activity in vitro but has yielded suboptimal outcomes in kick‐and‐kill HIV‐cure trials when administered as a 5 mg/m 2 infusion. We hypothesized that distinct pharmacokinetic targets exist between the pharmacodynamic goals of cytotoxicity for cancer therapy and latency reversal for HIV cure. To address this question, we designed an empirical modeling framework incorporating patient pharmacokinetics as a New Approach Methodology. Using clonal‐ and primary cell models of HIV‐1 latency with readouts for different stages of latency‐reversing activity, we performed exposure–response and dose‐fractionation studies to define pharmacokinetic drivers of efficacy in latency, then designed tailored dosing strategies to meet these targets in static‐ and dynamic‐culture systems, including a hollow‐fiber model. Across all systems, the only consistent pharmacokinetic parameter driving latency‐reversing activity, was RMD exposure time, with maximal activity achieved in cells exposed to ~4–6 ng/mL RMD for ≥ 20 hours (AUCs of ~80–120 ng*hour/mL). With current clinical‐dosing strategies achieving AUCs of 240–600 ng*hour/mL, the same outcome occurred only when RMD concentrations greatly exceeded a cytotoxicity threshold, suggesting response was a byproduct of cytotoxic processes rather than targeted latency reversal. These findings indicate that conventional oncologic dosing strategies for RMD might not be directly applicable to HIV‐1 latency reversal, offering a mechanistic explanation for suboptimal clinical outcomes. We provide proof‐of‐concept for RMD's limited clinical efficacy and propose a “low and slow” dosing strategy targeting time‐driven, toxicity‐minimized drug exposure, demonstrating how in vitro pharmacokinetic/pharmacodynamic investigations applying clinical pharmacokinetic data may inform dose optimization for clinical trials of latency reversal.